Trial · NCT01376557
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in HbA1c to Week 12 | 75 mg LX4211 qd | -0.42 | Standard Deviation 0.637 | % change | |
| Change From Baseline in HbA1c to Week 12 | 200 mg LX4211 qd | -0.52 | Standard Deviation 0.780 | % change | |
| Change From Baseline in HbA1c to Week 12 | 400 mg LX4211 qd | -0.92 | Standard Deviation 0.873 | % change | |
| Change From Baseline in HbA1c to Week 12 | 200 mg LX4211 Bid | -0.80 | Standard Deviation 0.932 | % change | |
| Change From Baseline in HbA1c to Week 12 | Placebo qd | -0.09 | Standard Deviation 0.770 | % change | |
| Number of Participants Achieving a HbA1c Value of <7% at Week 12 | 75 mg LX4211 qd | 16 | participants | ||
| Number of Participants Achieving a HbA1c Value of <7% at Week 12 | 200 mg LX4211 qd | 15 | participants | ||
| Number of Participants Achieving a HbA1c Value of <7% at Week 12 | 400 mg LX4211 qd | 22 | participants | ||
| Number of Participants Achieving a HbA1c Value of <7% at Week 12 | 200 mg LX4211 Bid | 17 | participants | ||
| Number of Participants Achieving a HbA1c Value of <7% at Week 12 | Placebo qd | 14 | participants | ||
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 | 75 mg LX4211 qd | -9.5 | Standard Deviation 27.35 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 | 200 mg LX4211 qd | -17.4 | Standard Deviation 40.45 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 | 400 mg LX4211 qd | -27.1 | Standard Deviation 38.48 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 | 200 mg LX4211 Bid | -26.9 | Standard Deviation 35.07 | mg/dL | |
| Change From Baseline in Fasting Plasma Glucose (FPG) to Week 12 | Placebo qd | 2.2 | Standard Deviation 45.35 | mg/dL | |
| Change From Baseline in Body Weight at Week 12 | 75 mg LX4211 qd | -0.995 | Standard Deviation 3.1130 | kg | |
| Change From Baseline in Body Weight at Week 12 | 200 mg LX4211 qd | -1.956 | Standard Deviation 2.5360 | kg | |
| Change From Baseline in Body Weight at Week 12 | 400 mg LX4211 qd | -1.848 | Standard Deviation 1.9641 | kg | |
| Change From Baseline in Body Weight at Week 12 | 200 mg LX4211 Bid | -2.477 | Standard Deviation 2.5610 | kg | |
| Change From Baseline in Body Weight at Week 12 | Placebo qd | -0.395 | Standard Deviation 1.9813 | kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01376557/results